Topics covered: Molecular Diagnostics, Increased M&A Activity in Diagnostics, Health Care Growth Sectors Identified, Health Care Consolidation Activity, Diagnostics Headwinds, Decentralized Testing
Companies covered: MDRNA, Inc., CEPHEID (NASDAQ:CPHD), Sequenom, Inc. (NASDAQ:SQNM), Qiagen N.V. (NASDAQ:QGEN), Neogen Corporation (NASDAQ:NEOG), Myriad Genetics, Inc. (NASDAQ:MYGN), Monsanto Company (NYSE:MON), Luminex Corporation (NASDAQ:LMNX), Hologic, Inc. (NASDAQ:HOLX), Haemonetics Corporation (NYSE:HAE), Genomic Health, Inc. (NASDAQ:GHDX), EXACT Sciences Corporation (NASDAQ:EXAS), Conagra Brands Inc. (NYSE:CAG), Becton, Dickinson and Company (NYSE:BDX), Abbott Laboratories (NYSE:ABT), Vical Incorporated (NASDAQ:VICL), ImmuCell Corporation (NASDAQ:ICCC), ZIOPHARM Oncology Inc (NASDAQ:ZIOP), Meridian Bioscience Inc. (NASDAQ:VIVO), Quidel Corporation (NASDAQ:QDEL), OraSure Technologies, Inc. (NASDAQ:OSUR), Laboratory Corporation of America Holdings (NYSE:LH), Quest Diagnostics Incorporated (NYSE:DGX), VolitionRX Limited (NYSEAMERICAN:VNRX), Organovo Holdings, Inc. (NASDAQ:ONVO), Cleveland BioLabs, Inc. (NASDAQ:CBLI), Zimmer Holdings, Inc. (NYSE:ZMH), Varian Medical Systems, Inc. (NYSE:VAR), Medtronic, Inc. (NYSE:MDT), Johnson & Johnson (NYSE:JNJ), Intuitive Surgical, Inc. (NASDAQ:ISRG), Covidien Ltd. (NYSE:COV)
